Hepatitis C, Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma, Current Information On Hepatitis C & treatments for the medical professional and patient.

Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced
Hepatocellular Carcinoma:
Results of a Randomized, Controlled Trial in a Single Institution

table 1. Baseline Characteristics of the Patients

	TAE Group (n = 40)	Control Group (n = 40)

Age (yr)	61 ± 9	64 ± 8
Sex distribution (male/female)	30/10	30/10
Etiology of hepatic cirrhosis
Hepatitis C virus	29	31
Cryptogenic	5	4
Alcohol	2	1
Hepatitis B virus	2	1
Others	2	3
Presence of ascites (%)	10 (25%)	7 (18%)
Constitutional syndrome (%)	9 (23%)	7 (18%)
Serum bilirubin (mg/dL)	1.2 ± 0.6	1.5 ± 0.7
Prothrombin activity (%)	81 ± 16	79 ± 14
Serum albumin (g/L)	35 ± 4	35 ± 5
Alanine transaminase (UI/L)	89 ± 57	101 ± 75
-Glutamyltranspeptidase (UI/L)	112 ± 114	119 ± 88
Alkaline phosphatase (UI/L)	303 ± 6	343 ± 201
Blood urea nitrogen (mg/dL)	18 ± 5	18 ± 5
-Fetoprotein
100 ng/mL	26	27
>100 ng/mL	14	13
Tumor stage
Solitary	8	11
Multinodular/massive	32	29
Tumor location
Unilobar	24	25
Bilobar	16	15
Child-Pugh score	5.8 ± 0.7	6.0 ± 1.1
Okuda’s stage (I/II)	27/13	27/13
PST (0/1/2)	27/11/2	27/11/2

NOTE. There were no significant differences between groups with respect to any of these variables.

[Return To Article]

Hepatitis C, Transarterial Embolization Versus Symptomatic Treatment in Patients With Advanced Hepatocellular Carcinoma, Current Information On Hepatitis C & treatments for the medical professional and patient.

Share

Follow Us

Download Our Free Reports

Inside You'll Discover:

Thank You!